Tarsus Pharmaceuticals, Inc.

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements